Transcriptome Analyses of Adipose Tissue Samples Identify EGFL6 as a Candidate Gene Involved in Obesity-Related Adipose Tissue Dysfunction in Children

• Main Authors: Biemann, R. (Author), Isermann, B. (Author), Kempf, E. (Author), Kirsten, H. (Author), Körner, A. (Author), Kühnapfel, A. (Author), Landgraf, K. (Author), Schlanstein, M. (Author), Scholz, M. (Author)
• Format: Article
• Language: English
• Published: MDPI 2022
• Subjects: adipocyte; adipocyte hypertrophy; adipose tissue; adipose tissue dysfunction; children; EGFL6; metabolic disease; obesity; transcriptome
• Online Access: View Fulltext in Publisher

 Obesity develops early in childhood and is accompanied by early signs of adipose tissue (AT) dysfunction and metabolic disease in children. In order to analyse the molecular processes during obesity-related AT accumulation in children, we investigated genome-wide expression profiles in AT samples, isolated adipocytes, and stromal vascular fraction (SVF) cells and assessed their relation to obesity as well as biological and functional AT parameters. We detected alterations in gene expression associated with obesity and related parameters, i.e., BMI SDS, adipocyte size, macrophage infiltration, adiponectin, and/or leptin. While differential gene expression in AT and adipocytes shared an enrichment in metabolic pathways and pathways related to extracellular structural organisation, SVF cells showed an overrepresentation in inflammatory pathways. In adipocytes, we found the strongest positive association for epidermal growth factor-like protein 6 (EGFL6) with adipocyte hypertrophy. EGFL6 was also upregulated during in vitro adipocyte differentiation. In children, EGFL6 expression was positively correlated to parameters of AT dysfunction and metabolic disease such as macrophage infiltration into AT, hs-CRP, leptin levels, and HOMA-IR. In conclusion, we provide evidence for early alterations in AT gene expression related to AT dysfunction in children and identified EGFL6 as potentially being involved in processes underlying the pathogenesis of metabolic disease. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.